EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) - A Randomized, Double-blind, Placebo-controlled Multicenter Study
Phase of Trial: Phase III
Latest Information Update: 12 Nov 2018
At a glance
- Drugs Evolocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms EVOPACS
- 12 Nov 2018 Trial design published in the Clinical Cardiology.
- 31 Aug 2018 Biomarkers information updated
- 14 Mar 2018 Status changed from not yet recruiting to recruiting.